Table 3 Safety endpoint and procedural adverse events

From: Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial

Eventa

Tailored (n = 187)

Anatomical (n = 183)

P valueb

Subjects with major procedure-related complications

5

5c

>0.99

 Cardiac tamponade or perforation

2

2

>0.99

 Bradycardia with pacemaker implantation

1

1

>0.99

 Severe cardiac decompensation

1

1

>0.99

 Puncture-site hemorrhage requiring transfusion

0

1

>0.99

 Transient phrenic nerve palsy

1

0

>0.99

 Pneumonia aspiration

0

1

>0.99

Subjects with minor procedure-related complications

15d

6d

0.07

 Fluid overloade

9

3

0.14

 Pericarditis or pericardial effusionf

4

0

0.12

 Vascular access complication

3

3

>0.99

 Post-ablation fever

1

0

>0.99

 Abnormal ECG requiring hospitalization

0

1

>0.99

Subjects with non-procedure-related adverse events

3

0

0.25

 Deathg

2

0

0.50

 Transient ischemic attack

1

0

>0.99

  1. aThe primary safety endpoint was a composite of death, cerebrovascular events, or treatment-related serious adverse events. Serious adverse events are reported for patients who underwent an ablation procedure, regardless of whether they completed at least 3 months of follow-up. There were no significant differences between groups.
  2. bTwo-sided Fisher’s exact test was used for the categorical data.
  3. cOne patient who had a severe cardiac decompensation was subsequently implanted with a pacemaker; accordingly, the individual components add to more than the total number of patients with any event.
  4. dTwo patients had vascular access complications and fluid overload events; one patient who had a mild pericardial effusion subsequently had a fluid overload event; accordingly, the individual components add to more than the total number of patients with any event.
  5. ePatients were treated with diuretics only and had favorable outcomes.
  6. fPatients were treated with corticosteroids or colchicine, and the events resolved without drainage or surgical intervention.
  7. gTwo patients died as a result of Guillain–Barré syndrome and sarcoma, 5 and 7 months after the ablation, respectively, without arrhythmia recurrence; thus, both deaths were classified as unrelated to the ablation procedure or cardiac disease.